GOG 209 study: optimal management of advanced endometrial cancer

New therapies to treat advanced endometrial cancer

Defining and advancing individualised medicine

6th International Workshop on Myeloma Pharmacogenomics and Novel Therapeutics

Developing technologies for personalised treatment

Genes, chromosomes and the treatment of bladder cancer

Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)

Development and expansion of the IFOM-IEO campus

Histology and non-histology driven therapy for soft tissue sarcomas and the Rare Cancers Europe initiative

Putting the theory of personalised medicine into practice

Personalised cancer medicine and research: Today’s best practice

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer